For the quarter ending 2026-03-31, GTBP had $2,112K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,833 | -23,031 | -3,114 | -2,209 |
| (increase) in operating lease right-of-use assets | - | - | - | 0 |
| Gain on extinguishment of debt | - | -798 | 0 | 998 |
| Stock based compensation | 46 | 46 | 379 | 7 |
| Unrealized gain on short-term investments | - | - | - | 0 |
| Gain on settlement of debt | - | 798 | 0 | 200 |
| Loss on initial recognition of greenshoe rights liability | - | 28,736 | - | - |
| Issuance of warrants for vrt waiver | - | 0 | 0 | 44 |
| Change in fair value of greenshoe rights liability | - | -11,413 | - | - |
| Change in fair value of warrant liability | -11 | 3 | -232 | -12 |
| (increase) decrease in prepaid expenses | -222 | -499 | -103 | 225 |
| Increase (decrease) in accounts payable and accrued expenses | 108 | 1,139 | -813 | -1,623 |
| Net cash used in operating activities | -2,468 | -4,021 | -3,677 | -5,216 |
| Sale of investments | - | - | - | 0 |
| Net cash provided by investing activities | - | - | - | 0 |
| Exercise of warrants for cash, net | 577 | 4,444 | 0 | 1,052 |
| Proceeds from issuance of series l convertible preferred stock and warrants, net | 4,003 | 4,005 | 1,062 | 5,441 |
| Payment of dividend on series l preferred stock | - | 144 | 85 | - |
| Net cash provided by financing activities | 4,580 | 8,305 | 977 | 6,493 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 2,112 | 4,284 | -2,700 | 1,277 |
| Cash and cash equivalents and restricted cash at beginning of period | 6,905 | 2,621 | 4,044 | - |
| Cash and cash equivalents and restricted cash at end of period | 9,017 | 6,905 | 2,621 | - |
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)